Table 3 Study visits
Assessment method | Screening | Onset (0 h) | 24 h | 10–14 days | 90-day follow-up |
|---|---|---|---|---|---|
Patient population | W | – | – | – | – |
History | W | – | – | – | – |
Physical examination | W | W | – | – | – |
CT/CTA | W | W | W | – | |
Confirmation of entry criteria | W | – | – | – | – |
Signing consent form | W | – | – | – | – |
Serum and urine test | W | – | – | – | – |
Concomitant medication or treatment | W | W | W | W | W |
GCS | W | W | W | W | – |
NIHSS | W | W | W | W | W |
BI | W | – | W | W | |
mRS | – | – | – | W | W |
Adverse events | w | w | w | w | W |
Summary of patient | – | – | – | – | W |